Lung Cancer Patient Is the First to Receive p53/Retrovirus Treatment
COLLEGEVILLE, Penn--A patient with advanced non-small-cell lung cancer has become the first to receive an injection of a p53/retrovirus gene therapy into existing tumor cells, Introgen Therapeutics, Inc. and RPR Gencell, a division of Rhône-Poulenc Rorer, have announced.
COLLEGEVILLE, Penn--A patient with advanced non-small-cell lungcancer has become the first to receive an injection of a p53/retrovirusgene therapy into existing tumor cells, Introgen Therapeutics,Inc. and RPR Gencell, a division of Rhône-Poulenc Rorer,have announced.
The phase I study is being conducted by Jack A. Roth, MD, at TheUniversity of Texas M.D. Anderson Cancer Center, where he is chairmanof the Department of Thoracic and Cardiovascular Surgery.
The retrovirus vector delivers normal p53 genes into cancer cellsin an attempt to restore normal cellular control. The patientreceived the dose into the tumor bed after surgical excision andwill be given four more doses.
Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer
September 18th 2018ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.
